Incomplete success of angioinhibitor therapy in cancer: Estimation of contribution of pro-angiogenic activity of patient thyroid hormone

Paul J. Davis, Murat Yalcin, Hung Yun Lin, Heng Yuan Tang, Aleck Hercbergs, John T. Leith, Faith B. Davis, Mary K. Luidens, Shaker A. Mousa

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Despite the obvious promise of the strategy, pharmaceutical angioinhibition has had variable success in clinical cancer management. Thyroid hormone is a potent pro-angiogenic factor. Endogenous circulating levels of proangiogenic thyroid hormone in cancer patients treated with anti-angiogenic drugs may contribute to host resistance to angioinhibition and explain, at least in part, the variable cancer chemotherapeutic responses obtained with anti-angiogenic agents. The chick chorioallantoic membrane (CAM) angiogenesis assay accepts human tumor xenografts and is a system in which individual patient blood samples can be tested in xenograft vasculature for anti-angiogenic content-including thyroid hormone-in the presence of angioinhibitory drug dose escalation. The assay may also be used to screen individual patient tumor biopsy xenografts for susceptibility to angioinhibition.

Original languageEnglish
Pages (from-to)441-445
Number of pages5
JournalJournal of Cancer Science and Therapy
Volume5
Issue number12
DOIs
Publication statusPublished - 2013

Fingerprint

Thyroid Hormones
Heterografts
Neoplasms
Therapeutics
Chorioallantoic Membrane
Angiogenesis Inhibitors
Angiogenesis Inducing Agents
Pharmaceutical Preparations
Biopsy

Keywords

  • Angiogenesis
  • Chick chorioallantoic membrane (CAM) assay
  • Integrin αvβ3
  • Thyroxine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Incomplete success of angioinhibitor therapy in cancer : Estimation of contribution of pro-angiogenic activity of patient thyroid hormone. / Davis, Paul J.; Yalcin, Murat; Lin, Hung Yun; Tang, Heng Yuan; Hercbergs, Aleck; Leith, John T.; Davis, Faith B.; Luidens, Mary K.; Mousa, Shaker A.

In: Journal of Cancer Science and Therapy, Vol. 5, No. 12, 2013, p. 441-445.

Research output: Contribution to journalArticle

Davis, Paul J. ; Yalcin, Murat ; Lin, Hung Yun ; Tang, Heng Yuan ; Hercbergs, Aleck ; Leith, John T. ; Davis, Faith B. ; Luidens, Mary K. ; Mousa, Shaker A. / Incomplete success of angioinhibitor therapy in cancer : Estimation of contribution of pro-angiogenic activity of patient thyroid hormone. In: Journal of Cancer Science and Therapy. 2013 ; Vol. 5, No. 12. pp. 441-445.
@article{94b668dc20244d6681dcfca5c0b9fcb1,
title = "Incomplete success of angioinhibitor therapy in cancer: Estimation of contribution of pro-angiogenic activity of patient thyroid hormone",
abstract = "Despite the obvious promise of the strategy, pharmaceutical angioinhibition has had variable success in clinical cancer management. Thyroid hormone is a potent pro-angiogenic factor. Endogenous circulating levels of proangiogenic thyroid hormone in cancer patients treated with anti-angiogenic drugs may contribute to host resistance to angioinhibition and explain, at least in part, the variable cancer chemotherapeutic responses obtained with anti-angiogenic agents. The chick chorioallantoic membrane (CAM) angiogenesis assay accepts human tumor xenografts and is a system in which individual patient blood samples can be tested in xenograft vasculature for anti-angiogenic content-including thyroid hormone-in the presence of angioinhibitory drug dose escalation. The assay may also be used to screen individual patient tumor biopsy xenografts for susceptibility to angioinhibition.",
keywords = "Angiogenesis, Chick chorioallantoic membrane (CAM) assay, Integrin αvβ3, Thyroxine",
author = "Davis, {Paul J.} and Murat Yalcin and Lin, {Hung Yun} and Tang, {Heng Yuan} and Aleck Hercbergs and Leith, {John T.} and Davis, {Faith B.} and Luidens, {Mary K.} and Mousa, {Shaker A.}",
year = "2013",
doi = "10.4172/1948-5956.1000238",
language = "English",
volume = "5",
pages = "441--445",
journal = "Journal of Cancer Science and Therapy",
issn = "1948-5956",
publisher = "OMICS Publishing Group",
number = "12",

}

TY - JOUR

T1 - Incomplete success of angioinhibitor therapy in cancer

T2 - Estimation of contribution of pro-angiogenic activity of patient thyroid hormone

AU - Davis, Paul J.

AU - Yalcin, Murat

AU - Lin, Hung Yun

AU - Tang, Heng Yuan

AU - Hercbergs, Aleck

AU - Leith, John T.

AU - Davis, Faith B.

AU - Luidens, Mary K.

AU - Mousa, Shaker A.

PY - 2013

Y1 - 2013

N2 - Despite the obvious promise of the strategy, pharmaceutical angioinhibition has had variable success in clinical cancer management. Thyroid hormone is a potent pro-angiogenic factor. Endogenous circulating levels of proangiogenic thyroid hormone in cancer patients treated with anti-angiogenic drugs may contribute to host resistance to angioinhibition and explain, at least in part, the variable cancer chemotherapeutic responses obtained with anti-angiogenic agents. The chick chorioallantoic membrane (CAM) angiogenesis assay accepts human tumor xenografts and is a system in which individual patient blood samples can be tested in xenograft vasculature for anti-angiogenic content-including thyroid hormone-in the presence of angioinhibitory drug dose escalation. The assay may also be used to screen individual patient tumor biopsy xenografts for susceptibility to angioinhibition.

AB - Despite the obvious promise of the strategy, pharmaceutical angioinhibition has had variable success in clinical cancer management. Thyroid hormone is a potent pro-angiogenic factor. Endogenous circulating levels of proangiogenic thyroid hormone in cancer patients treated with anti-angiogenic drugs may contribute to host resistance to angioinhibition and explain, at least in part, the variable cancer chemotherapeutic responses obtained with anti-angiogenic agents. The chick chorioallantoic membrane (CAM) angiogenesis assay accepts human tumor xenografts and is a system in which individual patient blood samples can be tested in xenograft vasculature for anti-angiogenic content-including thyroid hormone-in the presence of angioinhibitory drug dose escalation. The assay may also be used to screen individual patient tumor biopsy xenografts for susceptibility to angioinhibition.

KW - Angiogenesis

KW - Chick chorioallantoic membrane (CAM) assay

KW - Integrin αvβ3

KW - Thyroxine

UR - http://www.scopus.com/inward/record.url?scp=84893138616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893138616&partnerID=8YFLogxK

U2 - 10.4172/1948-5956.1000238

DO - 10.4172/1948-5956.1000238

M3 - Article

AN - SCOPUS:84893138616

VL - 5

SP - 441

EP - 445

JO - Journal of Cancer Science and Therapy

JF - Journal of Cancer Science and Therapy

SN - 1948-5956

IS - 12

ER -